Metformin use has been associated with a decreased risk of cancer and improvement in overall cancer survival rates. However, scant data available regarding metformin’s role in the risk of Gastrointestinal (GI) malignancies in patients with type II diabetes.
No takes yet. Share an insight, caveat, or question.
Gil et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: